Zanidatamab regimens improve survival for gastroesophageal cancer
First-line zanidatamab-hrii plus chemotherapy, without or with tislelizumab-jsgr, extended survival 24% and 35% vs. trastuzumab plus chemotherapy for those with locally advanced or...
First-line zanidatamab-hrii plus chemotherapy, without or with tislelizumab-jsgr, extended survival 24% and 35% vs. trastuzumab plus chemotherapy for those with locally advanced or...
In 2010, the CRASH-2 trial was published in the Lancet.[1] The authors randomized 20,211 trauma patients with, or at risk of, significant hemorrhage within 8 hours of injury to eit...
CG’s therapy cretostimogene cut the risk of recurrence by 68% when administered after surgery, far surpassing Wall Street’s expectations and lifting company shares.
A Cleveland Clinic-led trial found that pelacarsen reduced Lp(a) levels by 78.4% but failed to lower rates of major cardiovascular events compared to a placebo over nearly five yea...
SHANGHAI, Oct. 25, 2026 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announces that...
Use SocialBu to discover ideas, generate post drafts, and schedule them across your social channels.